Skip to main content
Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc — Investor Relations & Filings

Ticker · CNTA ISIN · US1523091007 LEI · 213800GIDAARDSKOI827 US Manufacturing
Open in API
Filings indexed 548 across all filing types
Latest filing 2022-06-09 Remuneration Information
Country GB United Kingdom
Listing US CNTA

About Centessa Pharmaceuticals plc

https://www.centessa.com/

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that utilizes a Research & Development innovation engine to discover and develop transformational medicines for patients. The company employs a data-driven approach to advance its portfolio of innovative assets. A key program in its pipeline is the development of potential best-in-class, orally administered orexin receptor 2 (OX2R) agonists for the treatment of sleep-wake disorders. Centessa's broader therapeutic focus often includes rare diseases and other areas with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
DEFINITIVE ADDITIONAL MATERIALS
Remuneration Information Classification · 95% confidence The document text is extremely short (159 characters) and only contains a reference to 'DEFA14A' and 'DEFINITIVE ADDITIONAL MATERIALS'. DEFA14A is a form related to executive compensation and director remuneration information. The document does not contain any detailed content but appears to be a header or title for such materials. Given the short length and the nature of the form, this is likely a filing related to remuneration information rather than the full report itself.
2022-06-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a strategic decision to discontinue a clinical development program, expected costs related to this decision, and an update on a corporate presentation. It also references a press release and a corporate presentation attached as exhibits. The document does not contain comprehensive financial statements or detailed financial analysis typical of annual or quarterly reports. It is primarily an event-driven disclosure about a significant corporate development and related financial impact estimates. Therefore, this filing fits the category of a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific report types.
2022-06-02 English
DEFINIITVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2022-05-23 English
FORM 4 SUBMISSION
Director's Dealing
2022-05-20 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-16 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 16, 2022, reporting the financial results for the quarter ended March 31, 2022. It includes a press release as Exhibit 99.1 announcing quarterly financial results. The text explicitly states it is a current report on Form 8-K and the content is a financial results announcement for a quarter, which aligns with an Earnings Release. The document length is 3749 characters, which is relatively short and typical for an earnings release announcement rather than a full interim report. The document does not contain detailed financial statements or substantive financial data itself but refers to a press release. According to the rules, an initial announcement of quarterly financial results (key highlights only) is classified as Earnings Release (ER).
2022-05-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.